|Bid||285.55 x 900|
|Ask||288.20 x 800|
|Day's range||279.46 - 287.86|
|52-week range||176.36 - 293.17|
|Beta (5Y monthly)||0.55|
|PE ratio (TTM)||29.71|
|Earnings date||27 Jul 2022 - 01 Aug 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||293.51|
If you hold on to a promising growth stock for five years, you should expect to accumulate some decent gains over that time. Investing in just the S&P 500 would have resulted in a nearly 60% increase in value -- and that's even after factoring in this year's bearish market. Five years ago, Vertex Pharmaceuticals (NASDAQ: VRTX) was coming off a year when its revenue soared by 65% to $1.7 billion.
Is a recession coming? Ark Invest CEO Cathie Wood thinks that one has already arrived. Economists surveyed by The Wall Street Journal put the odds of a recession over the next 12 months at 44%. Federal Reserve chairman Jerome Powell recently said that a recession is "a possibility," although the Fed is trying to avoid causing one with its interest rate hikes.
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $280.35, marking a +1.51% move from the previous day.